Alpha Cognition Inc. (ACOG) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.0x

Market Cap

$207.33M

MomentumView details →

1D Return

+3.37%

YTD Return

+45.27%

RSI (14)

57.1

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−6.0x

Market Cap

$207.33M

RSI (14)

57.1

MomentumView details →

1D Return

+3.37%

YTD Return

+45.27%

SummaryUpdated Jun 1, 2026

Alpha Cognition Inc. (NASDAQ:ACOG) is a clinical-stage biopharmaceutical company founded in 2000 and headquartered in Vancouver, Canada. The company was formerly known as Crystal Bridge Enterprises Inc. before changing its name in March 2021. Alpha Cognition focuses on developing treatments for neurodegenerative diseases, particularly Alzheimer's disease and amyotrophic lateral sclerosis (ALS). The company successfully transitioned from a pre-revenue clinical-stage entity to a commercial-stage company in 2025 with the launch of its flagship product ZUNVEYL for treating mild-to-moderate Alzheimer's disease.

Ask drillr about Alpha Cognition Inc. →

ProfitabilityView details →

Gross Margin

89.89%

Net Margin

−153.61%

EBITDA Margin

−180.73%

ROE (TTM)

−44.26%

ROA (TTM)

−36.33%

Asset Turnover

0.23x

GrowthView details →

Revenue YoY

+232.74%

EPS YoY

+31.77%

FCF YoY

—

Revenue CAGR 3Y

—

EPS CAGR 3Y

+42.08%

EBITDA YoY

−83.08%

EarningsView details →

EPS (Actual)

−$0.40

EPS Surprise

−2.00%

Beats (12Q)

4/12

Next Q EPS Est

−$0.34

Avg Surprise (4Q)

6.72%

Rev Surprise

36.86%

Capital & dividendView details →

Debt/Equity

0.00x

Current Ratio

9.03x

Quick Ratio

8.04x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

15.26M

Net Income (TTM)

−23.44M

Op. CF (TTM)

−30.91M

Next earningsNov 12, 2026 →

Latest newsMore news →

Alpha Cognition reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter.23d ago

Alpha Cognition Inc. received a European patent from the European Patent Office covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for treating mild-to-moderate Alzheimer's disease.38d ago

Similar companies

Muzero Acquisition Corp UnitMUZEU Karman Line Acquisition Corp. UnitsXTERU Newbury Street II Acquisition CorpNTWOU TRG Latin America Acquisitions Corp. UnitsTRGSU Paloma Acquisition Corp I Class A Ordinary SharesPALO A Paradise Acquisition Corp.ENHA Find similar companies →

Latest newsMore news →

Alpha Cognition reported second-quarter 2026 net product revenue of approximately $6 million from its Alzheimer's treatment ZUNVEYL, up about 71% sequentially from $3.5 million in the first quarter.23d ago Alpha Cognition Inc. received a European patent from the European Patent Office covering a crystalline solid form of benzgalantamine, the active ingredient in ZUNVEYL, for treating mild-to-moderate Alzheimer's disease.38d ago